10:02 AM EST - Valeant Pharmaceuticals International : announced that it has entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Solta Medical, for $2.92 per share in cash, which represents a 40% premium to Solta's closing share price on December 13,, the last trading day prior to announcement, or a transaction value of approximately $250 million. Valeant Pharmaceuticals International
shares T.VRX are trading up $1.50 at $114.57.
